美股异动 | 将推出独家口服睾酮疗法 Hims & Hers Health(HIMS.US)涨超7%

Core Insights - Hims & Hers Health (HIMS.US) stock price increased over 7%, reaching $51.39 as of the report [1] - The company announced a partnership with Marius Pharmaceuticals to exclusively launch an oral testosterone medication, KYZATREX®, on its platform in 2026 [1] - KYZATREX® has received FDA approval and offers a more convenient alternative to injections [1] Clinical Data - Clinical data indicates that KYZATREX® can restore normal testosterone levels in up to 96% of men [1] - The medication is reported to double the levels of "free testosterone," which is closely associated with energy, drive, and physical performance [1] - The drug maintains a low adverse reaction rate while enhancing efficacy [1]